Nkarta, Inc. reports results for the quarter ended June 30 - Earnings Summary
Nkarta, Inc. reports results for the quarter ended June 30 - Earnings Summary
Nkarta, Inc. NKTX.OQ reported a quarterly adjusted loss of 54 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -31 cents. The mean expectation of six analysts for the quarter was for a loss of 38 cents per share. Wall Street expected results to range from -40 cents to -34 cents per share.
Reported revenue was zero; analysts expected zero.
Nkarta, Inc.'s reported EPS for the quarter was a loss of 54 cents.
The company reported a quarterly loss of $40.37 million.
Nkarta, Inc. shares had fallen by 14.8% this quarter and gained 30.3% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 1.7% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Nkarta, Inc. is $11.00, about 78.1% above its last closing price of $2.41
This summary was machine generated from LSEG data August 10 at 10:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.38 | -0.54 | Missed |
Mar. 31 2026 | -0.37 | -0.37 | Met |
Dec. 31 2025 | -0.32 | -0.37 | Missed |
Sep. 30 2025 | -0.31 | -0.29 | Beat |
Recent news on Nkarta
See all newsNkarta, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biotech firm Nkarta posts Q2 net loss; cash runway into 2029
Brief: Nkarta Q2 EPS USD -0.54
Nkarta, Inc. expected to post a loss of 38 cents a share - Earnings Preview
Biotech experts want FDA drug reviews based on science, not politics (updated)